Welcome to our dedicated page for Cognyte Software SEC filings (Ticker: CGNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating the revenue impact of a new government contract or separating R&D devoted to threat-detection algorithms inside Cognyte Software’s filings can feel like searching for signals in cyber noise. Each 10-K and 10-Q is packed with security analytics jargon, while Form 4 disclosures of executive stock moves arrive without context.
Stock Titan resolves that pain. Our AI-powered summaries translate every Cognyte Software SEC document into plain language, flagging material risks, segment performance, and contract backlogs in seconds. Whether you need the Cognyte Software insider trading Form 4 transactions or the latest Cognyte Software quarterly earnings report 10-Q filing, we deliver real-time alerts as soon as EDGAR posts them.
Common questions—“How do I read Cognyte’s 10-K?” or “What changed in yesterday’s 8-K material event?”—are answered on the spot. Long-tail queries such as “understanding Cognyte Software SEC documents with AI”, “Cognyte Software annual report 10-K simplified”, and “Cognyte Software proxy statement executive compensation” all point here because we connect filing types to what matters: how recurring subscription revenue scales, where customer concentration risks emerge, and when executives trade shares.
- AI-powered highlights and plain-English explanations
- Real-time Cognyte Software Form 4 insider transactions alerts
- Interactive charts that compare quarters and spotlight segment trends
- One-click access to Cognyte Software 8-K material events explained
- Downloadable tables for deeper Cognyte Software earnings report filing analysis
Stop scrolling through hundreds of pages. With Stock Titan, Cognyte Software SEC filings are explained simply, allowing you to focus on decisions, not deciphering documents.
UBS AG is offering Trigger Autocallable Contingent Yield Notes (unsubordinated, unsecured debt) linked to Regeneron Pharmaceuticals, Inc. common stock. The notes have an expected 30-month term, issuing 16 Jul 2025 and maturing 18 Jan 2028, with quarterly observation dates. Investors receive a fixed contingent coupon of 9.01 %–9.87 % p.a. ($0.2253–$0.2468 per $10 note) only if Regeneron’s closing price on an observation date is at least 60 % of its initial level (the “coupon barrier”).
Automatic call: The notes are redeemed early at par plus the quarterly coupon if Regeneron closes at or above its initial level on any observation date before final valuation. Early call may occur as soon as the first quarter, creating reinvestment risk.
Principal repayment: • If not called and the final level is ≥ the 60 % downside threshold, investors receive full principal.
• If the final level is < the downside threshold, repayment equals $10 × (1 + underlying return), resulting in a dollar-for-dollar loss beyond 40 % decline; maximum loss is 100 % of principal.
Key economics
- Issue price: $10; minimum purchase 100 notes ($1,000).
- Estimated initial value: $9.47–$9.72 (reflects underwriting discount, hedging and funding costs).
- Underwriting discount: $0.175 per note (1.75 %).
Risk highlights
- Market risk identical to holding Regeneron below the 60 % threshold at maturity.
- No participation in upside beyond fixed coupons; dividends on Regeneron are foregone.
- Credit risk of UBS: all payments depend on UBS AG’s ability to pay; notes are not insured.
- Liquidity risk: notes will not be listed; secondary market, if any, may be illiquid and priced below issue price.
- Conflicts of interest: UBS entities act as issuer, distributor, calculation agent and market maker.
- Tax treatment uncertain; UBS treats notes as prepaid derivatives with ordinary-income coupons.
Investor suitability: suitable only for investors who (1) can tolerate potential total loss, (2) believe Regeneron will remain above 60 % of its initial level, (3) are comfortable with UBS credit exposure, and (4) accept limited liquidity and capped return.
Legal & General Group Plc and four affiliated investment entities have filed Amendment No. 1 to Schedule 13G reporting their aggregate beneficial ownership of Radware Ltd. (NASDAQ: RDWR) ordinary shares as of 31 December 2023.
- Aggregate position: 2,115,897 shares, representing 5.03 % of Radware’s outstanding ordinary shares.
- Voting/Dispositive power: All shares are held with shared voting and dispositive power; none are held with sole authority.
- Reporting entities: (i) Legal & General Group Plc (parent); (ii) Legal & General Investment Management Ltd; (iii) LGIM Managers (Europe) Ltd; (iv) Legal & General UCITS ETF Plc; (v) Legal & General Investment Management America Inc.
- Subsidiary breakdown shows LGIM Managers (Europe) Ltd and Legal & General UCITS ETF Plc each controlling 2,081,228 shares (≈4.9 %), while LGIM America holds 1,700 shares (≈0 %).
- The filing is made pursuant to Rule 13d-1(b), indicating a passive, non-activist investment.
- Certification is signed by Mary Ann Colledge, Head of Conduct Advisory, on 07 February 2025.
This disclosure signals that one of the UK’s largest asset managers now crosses the 5 % reporting threshold in Radware, adding a sizeable institutional holder to the share register. No strategic intentions, transactions, or changes in control are indicated in the filing.
Preliminary Pricing Supplement Overview
UBS AG is offering unsubordinated, unsecured Phoenix Autocallable Buffer Notes with Memory Interest linked to the common stock of CrowdStrike Holdings, Inc. (ticker CRWD). The Notes have an expected 54-week term, a $1,000 denomination and will settle on 16 July 2025. They are designed to provide quarterly contingent interest payments of at least $51.625 per Note (5.1625% per quarter) when CrowdStrike’s closing price on an observation date is at or above the Interest Barrier (80 % of the initial price). Missed coupons can be recovered later through the “memory” feature if the barrier condition is subsequently met.
Autocall & Principal Repayment Mechanics
- Automatic Call: If CRWD closes at or above the Initial Price on any quarterly Autocall Observation Date, the Notes are redeemed early at par plus any due and unpaid contingent interest.
- Downside Buffer: If not called, full principal is repaid at maturity only if CRWD’s Final Price is ≥ the Downside Threshold (also 80 % of Initial Price).
- Loss Exposure: Should the Final Price fall below the Downside Threshold, investors receive a cash equivalent based on a 1.25 : 1 loss ratio—i.e., principal erodes 1.25 % for every 1 % CRWD falls below the threshold, potentially to zero.
Key Dates
Trade Date: 11 Jul 2025 | Valuation Date: 24 Jul 2026 | Maturity / Call Settlement: 29 Jul 2026.
Autocall / Interest Observation Dates: 24 Oct 2025, 26 Jan 2026, 24 Apr 2026, and the Valuation Date.
Pricing / Distribution
- Issue price: $1,000 per Note; underwriting discount: $10; proceeds to UBS: $990.
- Estimated initial value: $954.20 – $984.20 (reflects internal models & funding spread).
- Minimum investment: 10 Notes ($10,000).
- Placement agents: J.P. Morgan Securities LLC and affiliates; UBS Securities LLC acts as lead and will make a secondary market if it chooses.
Risk Highlights
- Credit exposure to UBS AG; payments depend on issuer solvency.
- No exchange listing; liquidity likely thin, bid-offer spreads wide.
- Missed coupons possible in volatile markets; investors forego CRWD dividends and upside appreciation.
- Tax treatment uncertain; intended characterization is prepaid derivative with ordinary-income coupons.
- FINMA resolution powers could subject holders to write-down or conversion should UBS face distress.
Illustrative Scenarios
Hypothetical examples show total returns ranging from +20.65 % (all coupons received, no call, CRWD ≥ barrier) to –44.84 % (no call, CRWD – 60 %, buffer breached). Investors must be able to tolerate loss of principal and reinvestment risk if called early.
Investor Suitability
Appropriate for sophisticated investors seeking elevated contingent income, comfortable with single-stock volatility, credit risk, illiquidity, potential tax complexity and loss of some or all capital.
Legal & General Group Plc and four asset-management affiliates filed Amendment No. 1 to Schedule 13G disclosing passive ownership of 2,965,994 shares of Mitek Systems, Inc. (MITK) common stock as of 31 Dec 2021. The position represents approximately 6.6 % of MITK’s outstanding shares, giving the group shared voting and dispositive power over virtually the entire block. No sole voting or dispositive authority is claimed, underscoring that the stake is held across index and ETF vehicles managed by LGIM rather than for activist purposes. The U.K. and Ireland-based entities account for nearly all holdings, while the U.S. subsidiary owns only 12,999 shares (<0.03 % of the class). Filing as a financial institution (FI) under Rule 13d-1(b) confirms the investment is passive and subject to routine 13G reporting rather than 13D activism.
Key takeaways for investors: (1) the addition/confirmation of a well-known global asset manager as a >5 % holder can enhance MITK’s institutional ownership base and trading liquidity; (2) because authority is shared among multiple funds, the risk of concentrated voting influence is low; and (3) future changes in LGIM fund mandates could still affect MITK’s float, so monitoring subsequent 13G updates remains prudent.